Sinopharm Group (1099) Q1 2025 earnings summary

Executive summary

• Sinopharm Group reported unaudited financial results for the three months ended 31 March 2025, prepared under PRC GAAP.

Financial highlights

• Total operating revenue was RMB 141.66 billion, down 3.8% year-over-year from RMB 147.27 billion.

• Net profit attributable to equity holders was RMB 1.46 billion, up 2.6% year-over-year from RMB 1.42 billion.

• Operating profit was RMB 2.93 billion, down from RMB 3.10 billion year-over-year.

• Basic and diluted EPS were both RMB 0.47, compared to RMB 0.46 in the prior year period.

• Net cash used in operating activities was RMB 34.28 billion, an improvement from RMB 47.48 billion used in the prior year period.

Segment performance

• The parent company reported operating revenue of RMB 5.21 billion, up from RMB 4.91 billion year-over-year.

• Parent company net profit was RMB 271.53 million, a significant increase from RMB 48.41 million year-over-year.